Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 12 | 2025 | 109 | 3.820 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 7 | 2025 | 9 | 3.570 |
Why?
|
| Astigmatism | 5 | 2024 | 10 | 3.420 |
Why?
|
| Cataract | 6 | 2024 | 25 | 3.410 |
Why?
|
| Corneal Diseases | 11 | 2022 | 21 | 3.340 |
Why?
|
| Lenses, Intraocular | 7 | 2025 | 18 | 3.150 |
Why?
|
| Refraction, Ocular | 8 | 2025 | 23 | 2.790 |
Why?
|
| Phacoemulsification | 6 | 2025 | 19 | 2.600 |
Why?
|
| Cornea | 16 | 2024 | 65 | 2.600 |
Why?
|
| Cataract Extraction | 5 | 2024 | 29 | 2.380 |
Why?
|
| Keratoconus | 5 | 2024 | 8 | 2.230 |
Why?
|
| Surgeons | 3 | 2022 | 49 | 2.190 |
Why?
|
| Lens Implantation, Intraocular | 6 | 2025 | 18 | 1.740 |
Why?
|
| Pseudophakia | 2 | 2025 | 5 | 1.540 |
Why?
|
| Contact Lenses | 3 | 2022 | 6 | 1.480 |
Why?
|
| Humans | 54 | 2025 | 27168 | 1.340 |
Why?
|
| Retrospective Studies | 18 | 2025 | 2453 | 1.300 |
Why?
|
| Vision Disorders | 2 | 2020 | 38 | 1.210 |
Why?
|
| Tomography, Optical Coherence | 4 | 2023 | 89 | 1.190 |
Why?
|
| Keratitis | 2 | 2022 | 28 | 1.190 |
Why?
|
| Eye Infections, Bacterial | 2 | 2022 | 122 | 1.060 |
Why?
|
| Biometry | 8 | 2024 | 20 | 1.060 |
Why?
|
| Endothelium, Corneal | 5 | 2024 | 8 | 1.020 |
Why?
|
| Sclera | 2 | 2022 | 11 | 0.960 |
Why?
|
| Descemet Membrane | 3 | 2021 | 4 | 0.920 |
Why?
|
| Corneal Neovascularization | 1 | 2024 | 3 | 0.910 |
Why?
|
| Photochemotherapy | 1 | 2024 | 40 | 0.880 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2024 | 104 | 0.850 |
Why?
|
| Limbus Corneae | 2 | 2020 | 3 | 0.790 |
Why?
|
| Fluorometholone | 1 | 2022 | 4 | 0.790 |
Why?
|
| Axial Length, Eye | 6 | 2023 | 9 | 0.780 |
Why?
|
| Microsporidia | 1 | 2022 | 5 | 0.780 |
Why?
|
| Microsporidiosis | 1 | 2022 | 4 | 0.770 |
Why?
|
| Female | 22 | 2025 | 14662 | 0.750 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2021 | 2 | 0.750 |
Why?
|
| Refractive Errors | 1 | 2021 | 6 | 0.750 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2021 | 4 | 0.740 |
Why?
|
| Corneal Opacity | 1 | 2021 | 4 | 0.740 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2021 | 23 | 0.710 |
Why?
|
| Terminology as Topic | 1 | 2020 | 53 | 0.700 |
Why?
|
| Comprehension | 1 | 2019 | 18 | 0.640 |
Why?
|
| Informed Consent | 1 | 2019 | 24 | 0.630 |
Why?
|
| Preoperative Care | 1 | 2019 | 76 | 0.620 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 90 | 0.620 |
Why?
|
| Middle Aged | 15 | 2025 | 6913 | 0.610 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 87 | 0.610 |
Why?
|
| Charles Bonnet Syndrome | 1 | 2018 | 1 | 0.600 |
Why?
|
| Corneal Stroma | 3 | 2023 | 6 | 0.590 |
Why?
|
| Optics and Photonics | 5 | 2024 | 23 | 0.590 |
Why?
|
| Anxiety | 1 | 2019 | 140 | 0.590 |
Why?
|
| Refractive Surgical Procedures | 1 | 2017 | 1 | 0.570 |
Why?
|
| Male | 18 | 2025 | 13041 | 0.570 |
Why?
|
| Prosthesis Fitting | 3 | 2022 | 5 | 0.550 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 989 | 0.540 |
Why?
|
| Aged | 8 | 2025 | 5234 | 0.510 |
Why?
|
| Corneal Endothelial Cell Loss | 2 | 2024 | 2 | 0.510 |
Why?
|
| Keratomileusis, Laser In Situ | 2 | 2024 | 3 | 0.500 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 1944 | 0.470 |
Why?
|
| Achromobacter denitrificans | 1 | 2013 | 2 | 0.440 |
Why?
|
| Myopia | 2 | 2024 | 18 | 0.440 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2013 | 21 | 0.430 |
Why?
|
| Choroid Diseases | 1 | 2012 | 1 | 0.410 |
Why?
|
| Fluorescein Angiography | 1 | 2012 | 16 | 0.410 |
Why?
|
| Optic Disk | 1 | 2012 | 8 | 0.410 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 104 | 0.410 |
Why?
|
| Choroid | 1 | 2012 | 20 | 0.400 |
Why?
|
| Brain | 1 | 2018 | 712 | 0.400 |
Why?
|
| Cocaine-Related Disorders | 2 | 2003 | 17 | 0.400 |
Why?
|
| Corneal Injuries | 2 | 2022 | 11 | 0.390 |
Why?
|
| Keratoplasty, Penetrating | 2 | 2022 | 2 | 0.380 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 751 | 0.380 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2022 | 24 | 0.380 |
Why?
|
| Prospective Studies | 3 | 2022 | 1221 | 0.360 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 931 | 0.360 |
Why?
|
| Internship and Residency | 1 | 2014 | 228 | 0.350 |
Why?
|
| Calciphylaxis | 1 | 2009 | 4 | 0.340 |
Why?
|
| Penile Diseases | 1 | 2009 | 9 | 0.330 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2009 | 10 | 0.330 |
Why?
|
| Lasers | 3 | 2023 | 67 | 0.310 |
Why?
|
| Treatment Outcome | 2 | 2025 | 2286 | 0.300 |
Why?
|
| Heart Failure | 2 | 2003 | 234 | 0.290 |
Why?
|
| United States | 3 | 2024 | 2068 | 0.290 |
Why?
|
| Corneal Topography | 2 | 2024 | 3 | 0.280 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2024 | 74 | 0.240 |
Why?
|
| Prosthesis Design | 1 | 2025 | 85 | 0.240 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2024 | 111 | 0.230 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2024 | 37 | 0.230 |
Why?
|
| Enoxaparin | 1 | 2024 | 37 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 498 | 0.220 |
Why?
|
| Double-Blind Method | 2 | 2022 | 405 | 0.210 |
Why?
|
| Interferometry | 1 | 2023 | 11 | 0.210 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 367 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 177 | 0.210 |
Why?
|
| Hyperthyroidism | 1 | 2003 | 10 | 0.210 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2022 | 22 | 0.200 |
Why?
|
| Loteprednol Etabonate | 1 | 2022 | 2 | 0.200 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 73 | 0.200 |
Why?
|
| Collagen | 1 | 2023 | 147 | 0.200 |
Why?
|
| Ophthalmic Solutions | 1 | 2022 | 27 | 0.200 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 39 | 0.200 |
Why?
|
| Extracellular Matrix | 1 | 2023 | 111 | 0.200 |
Why?
|
| Estriol | 1 | 2022 | 3 | 0.200 |
Why?
|
| Estrone | 1 | 2022 | 5 | 0.200 |
Why?
|
| Intraoperative Complications | 1 | 2022 | 47 | 0.190 |
Why?
|
| Aortic Aneurysm | 1 | 2002 | 15 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 36 | 0.190 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2002 | 43 | 0.190 |
Why?
|
| Gonadotropins | 1 | 2021 | 22 | 0.190 |
Why?
|
| Graft Rejection | 1 | 2022 | 34 | 0.190 |
Why?
|
| Hormones | 1 | 2021 | 41 | 0.190 |
Why?
|
| Receptors, Steroid | 1 | 2022 | 26 | 0.190 |
Why?
|
| Heart Conduction System | 1 | 2003 | 270 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 73 | 0.180 |
Why?
|
| Punctal Plugs | 1 | 2021 | 3 | 0.180 |
Why?
|
| Dry Eye Syndromes | 1 | 2021 | 5 | 0.180 |
Why?
|
| Aorta | 1 | 2002 | 123 | 0.180 |
Why?
|
| Immunoconjugates | 1 | 2021 | 17 | 0.180 |
Why?
|
| Adult | 8 | 2024 | 7506 | 0.180 |
Why?
|
| Exosomes | 1 | 2022 | 92 | 0.170 |
Why?
|
| Vaccination | 1 | 2022 | 177 | 0.170 |
Why?
|
| Equipment Design | 1 | 2021 | 212 | 0.170 |
Why?
|
| Single-Blind Method | 1 | 2019 | 43 | 0.160 |
Why?
|
| Glucocorticoids | 2 | 2024 | 114 | 0.160 |
Why?
|
| Digoxin | 1 | 1998 | 8 | 0.150 |
Why?
|
| Cardiotonic Agents | 1 | 1998 | 25 | 0.150 |
Why?
|
| Remission, Spontaneous | 1 | 2018 | 8 | 0.150 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1998 | 117 | 0.140 |
Why?
|
| Tears | 3 | 2022 | 10 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 213 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 247 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 466 | 0.120 |
Why?
|
| Child | 1 | 2021 | 2158 | 0.120 |
Why?
|
| Long QT Syndrome | 2 | 2006 | 12 | 0.110 |
Why?
|
| Cadaver | 1 | 2014 | 57 | 0.110 |
Why?
|
| Stem Cells | 1 | 2014 | 113 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 135 | 0.100 |
Why?
|
| Fundus Oculi | 1 | 2012 | 15 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 205 | 0.100 |
Why?
|
| Cell Count | 2 | 2009 | 85 | 0.100 |
Why?
|
| Eye | 2 | 2022 | 35 | 0.090 |
Why?
|
| Uremia | 1 | 2010 | 5 | 0.090 |
Why?
|
| Calcinosis | 1 | 2010 | 25 | 0.090 |
Why?
|
| Retinal Diseases | 1 | 2011 | 45 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 64 | 0.090 |
Why?
|
| Gangrene | 1 | 2009 | 4 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 20 | 0.080 |
Why?
|
| Penis | 1 | 2009 | 16 | 0.080 |
Why?
|
| Skin | 1 | 2010 | 140 | 0.080 |
Why?
|
| Cardiology | 1 | 2010 | 47 | 0.080 |
Why?
|
| Corneal Transplantation | 1 | 2009 | 1 | 0.080 |
Why?
|
| Intraocular Pressure | 1 | 2009 | 61 | 0.080 |
Why?
|
| Glaucoma | 1 | 2009 | 52 | 0.080 |
Why?
|
| Contrast Media | 1 | 2010 | 94 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 160 | 0.070 |
Why?
|
| Prognosis | 1 | 2009 | 763 | 0.070 |
Why?
|
| Electrocardiography | 2 | 2006 | 391 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2009 | 606 | 0.060 |
Why?
|
| Receptors, LHRH | 1 | 2024 | 17 | 0.060 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2024 | 1 | 0.060 |
Why?
|
| Anterior Chamber | 1 | 2024 | 6 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2024 | 153 | 0.050 |
Why?
|
| Torsades de Pointes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Systole | 1 | 2003 | 24 | 0.050 |
Why?
|
| Young Adult | 2 | 2024 | 2633 | 0.050 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2003 | 19 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 78 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2003 | 67 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 397 | 0.050 |
Why?
|
| Immersion | 1 | 2022 | 4 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2024 | 707 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2003 | 64 | 0.050 |
Why?
|
| Mydriatics | 1 | 2022 | 6 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2024 | 293 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 5 | 0.050 |
Why?
|
| Adhesives | 1 | 2022 | 5 | 0.050 |
Why?
|
| Amnion | 1 | 2022 | 4 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 17 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 45 | 0.050 |
Why?
|
| Estrogen Receptor beta | 1 | 2022 | 13 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 25 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2022 | 60 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 26 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 105 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 153 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2022 | 89 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 73 | 0.050 |
Why?
|
| Wound Healing | 1 | 2022 | 113 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 199 | 0.050 |
Why?
|
| Povidone-Iodine | 1 | 2021 | 8 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 23 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2021 | 33 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 26 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 95 | 0.040 |
Why?
|
| Renal Dialysis | 2 | 2011 | 52 | 0.040 |
Why?
|
| Cell Movement | 1 | 2022 | 353 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 934 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2022 | 978 | 0.040 |
Why?
|
| Biomarkers | 1 | 2022 | 738 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 1998 | 43 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 1998 | 61 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 32 | 0.040 |
Why?
|
| Hemodynamics | 1 | 1998 | 220 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 589 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1998 | 365 | 0.030 |
Why?
|
| Anti-Allergic Agents | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vitamin A | 1 | 2014 | 25 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 142 | 0.030 |
Why?
|
| Hyperoxaluria | 1 | 2011 | 1 | 0.020 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pyridoxine | 1 | 2011 | 1 | 0.020 |
Why?
|
| Subretinal Fluid | 1 | 2011 | 1 | 0.020 |
Why?
|
| Oxalates | 1 | 2011 | 3 | 0.020 |
Why?
|
| Papilledema | 1 | 2011 | 8 | 0.020 |
Why?
|
| Nystagmus, Pathologic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Transaminases | 1 | 2011 | 10 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 82 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2011 | 52 | 0.020 |
Why?
|
| Electroretinography | 1 | 2011 | 173 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2010 | 8 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 19 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 25 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 67 | 0.020 |
Why?
|
| Air | 1 | 2009 | 23 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2009 | 68 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 150 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 143 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 104 | 0.020 |
Why?
|
| Microspheres | 1 | 2009 | 48 | 0.020 |
Why?
|
| Reoperation | 1 | 2009 | 144 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 235 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2010 | 218 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 965 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2006 | 45 | 0.020 |
Why?
|
| Risk Factors | 1 | 2010 | 2038 | 0.010 |
Why?
|